Close Menu

coronavirus

Breaking news on coronavirus testing, with real-time reporting on assays to detect the SARS-CoV2 coronavirus, which causes COVID-19. 

Check out our Coronavirus Test Tracker for the latest information on the regulatory status of these tests in the US, European, and Asian markets.

High-throughput sample prep is becoming critical to COVID-19 testing scale-up, but some labs are experiencing shortages at this stage in the testing workflow.

Of the 28 companies in the index, 21 firms saw their stock prices increase throughout the first half of the year, while seven firms' share prices decreased.

Issued last week, the guidance said insurers were not required to reimburse such testing, which could impact coverage in schools, workplaces, and other settings.

Earlier this month Centogene said that previously acquired laboratory space in Hamburg is now exclusively performing SARS-CoV-2 testing.

The latest Emergency Use Authorization is for an ELISA-based test for detecting immunoglobulin M antibodies against SARS-CoV-2 in human serum.

Yale researchers said that they anticipate their RNA extraction-free saliva assay will make testing more scalable, affordable, and available to the public.

Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased. 

The Lexington, Massachusetts-based company has launched a two-hour SARS-CoV-2 test on its fully-automated instrument, the T2Dx.

Developed by the Ragon Institute, the ELISA-based test measures antibodies that bind to the receptor binding domain of the SARS-CoV-2 spike protein.

The tests were developed by Psomagen, Acupath Laboratories, and BioTNS, and the nasal swab self-collection kit is offered by Kroger Health.

Pages